Financials · TVRD

Tvardi Therapeutics Inc. (TVRD) financials

For the twelve months ended Sep 30, 2026, Tvardi Therapeutics Inc. reported -$26.66M of net income.

Net income, TTM
-$26.66M
Cash
$22.27M
Market cap
$14.7M
Annual revenue$7.14M
FY2016FY2024
Annual net income-$18.21M
FY2016FY2025
Annual free cash flow-$19.35M
FY2016FY2024

TVRD revenue and earnings growth

TVRD net incomeQ3 2026-$6.12M

TVRD net income was -$6.12M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$5.53M a year earlier. For the full fiscal 2025 it was -$18.21M, compared with -$29.40M in fiscal 2024.

TVRD EPSQ3 2026-$0.48

TVRD diluted EPS was -$0.48 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.59 a year earlier. For the full fiscal 2025 it was -$3.26.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue-$7.14M$20.97M$41.87M$23.03M$135.08M$19.89M$13.47M$911.0K$86.0K
Cost of revenue----$0-----
Gross profit----$23.03M-----
Research and development$18.01M$23.65M$108.51M$91.88M$82.70M$107.85M$113.82M$75.53M$48.52M$49.25M
Selling, general and admin$8.74M$4.46M$27.78M$30.26M$29.41M$21.85M$17.75M$15.32M$11.87M$9.23M
Operating income-$26.75M-$28.11M-$121.50M-$87.53M-$89.08M$5.38M-$111.68M-$77.38M-$59.48M-$58.40M
Pre-tax income--$71.27M-$118.51M-$85.47M-$88.44M$7.72M-$107.19M-$74.40M-$58.33M-$57.75M
Income tax$0$0$0$0$0-$691.0K-$816.0K-$389.0K-$204.0K-$468.0K
Net income-$18.21M-$29.40M-$118.51M-$85.47M-$88.44M$8.41M-$106.37M-$74.01M-$58.13M-$57.28M
EPS, basic-$2.46-$11.42-$945.36-$688.32-$751.68$77.76-$1075.68-$889.92-$803.52-$907.20
EPS, diluted-$3.26-$11.42-$945.36-$688.32-$751.68$77.76-$1075.68-$889.92-$803.52-$907.20
Diluted shares7.8M2.6M125,345.056124,198.056117,404.549110,914.42198,771.60483,085.15372,228.80163,145.852

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$20.73M$31.61M$22.92M$64.15M$13.86M$32.09M$18.71M$15.85M$10.16M$13.56M
Short-term investments$10.08M---------
Receivables-$407.0K$2.77M$3.26M------
Inventory-$900.0K$2.82M$2.38M$2.58M-----
Current assets$31.54M$31.69M$116.16M$168.91M$173.29M$195.06M$165.66M$168.14M$95.06M$61.45M
Total assets$32.07M$35.20M$125.84M$182.24M$247.06M$271.16M$232.96M$190.82M$97.00M$63.83M
Current liabilities$11.04M$10.37M$25.59M$23.46M$17.62M$18.48M$42.89M$40.45M$8.51M$11.53M
Long-term debt-$30.26M--------
Total debt-$30.26M--------
Total liabilities$11.13M$40.83M$68.76M$23.46M------
Shareholders' equity$20.95M-$91.13M-$62.06M$158.78M$227.52M$249.00M$186.71M$133.63M$86.78M$50.73M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow-$23.50M-$18.30M-$92.08M-$78.73M-$60.09M-$5.49M-$109.22M-$22.30M-$54.83M-$47.38M
Capital expenditures-$1.05M$2.38M$43.0K$39.0K$349.0K$18.0K$73.0K$58.0K$717.0K
Free cash flow--$19.35M-$94.45M-$78.77M-$60.13M-$5.84M-$109.24M-$22.37M-$54.88M-$48.10M
Investing cash flow-$10.08M$48.74M$43.46M$128.71M-$4.75M-$20.27M-$30.52M-$82.82M-$36.50M$45.02M
Financing cash flow$22.70M$27.00M$38.15M$311.0K$46.61M$39.14M$142.60M$110.81M$87.92M$123.0K
Stock-based compensation$1.40M$319.0K$13.73M$17.73M$20.79M$14.84M$12.57M$9.48M$5.79M$2.80M
Depreciation and amortization$95.0K$95.0K$259.0K$248.0K$248.0K$209.0K$198.0K$370.0K$495.0K$1.47M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY--66.0%-49.9%81.8%-83.0%579.3%47.6%1378.5%959.3%-97.7%
Gross margin----100.0%-----
Operating margin--393.8%-579.4%-209.1%-386.8%4.0%-561.6%-574.5%-6529.6%-67907.0%
Net margin--411.9%-565.2%-204.2%-384.1%6.2%-534.9%-549.5%-6380.4%-66604.7%
Free cash flow margin--271.1%-450.5%-188.2%-261.1%-4.3%-549.3%-166.1%-6024.7%-55927.9%
Return on equity-87.0%---53.8%-38.9%3.4%-57.0%-55.4%-67.0%-112.9%
Return on assets-56.8%-83.5%-94.2%-46.9%-35.8%3.1%-45.7%-38.8%-59.9%-89.7%
Current ratio2.863.064.547.209.8410.553.864.1611.185.33

Source: XBRL data Tvardi Therapeutics Inc. files with the SEC, latest filing dated Nov 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-12, first reported Mar 11, 2025; 1-for-36, first reported May 13, 2025.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

TVRD peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
TVRD---$26.66M-$14.7M
LLY$86.46B+45.5%$27.58B31.9%$1.35T
JNJ$99.33B+7.8%$16.09B16.2%$680.19B
ABBV$66.01B+10.7%$10.34B15.7%$520.65B
MRK$67.38B+4.9%$2.45B3.6%$356.13B
NVS$54.53B+8.4%$13.98B25.6%$305.69B
AZN$58.74B+8.6%$10.22B17.4%$285.36B
ABT$48.23B+10.0%$4.70B9.7%$186.10B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$184.18B

TVRD FAQ

4 questions
  • Is TVRD profitable?
    No. Tvardi Therapeutics Inc. reported a net loss of $26.66M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does TVRD have?
    Tvardi Therapeutics Inc. reported $22.27M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • When did TVRD last report financial results?
    The latest statements here come from Tvardi Therapeutics Inc.'s 10-Q filed on Nov 13, 2026, covering the period ended Sep 30, 2026.
  • Where does this TVRD financial data come from?
    Quantisnow builds these statements from the structured XBRL data Tvardi Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.